Skip to main content

Table 2 Stratified analysis of the MDR1 3435C > T polymorphism on cancer risk

From: The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case–control studies

Genetic model

 

Homozygote

Heterozygote

Dominant model

Recessive model

 

Sample size (case/control)

OR (95% CI)

p h

I 2 (%)

OR (95% CI)

p h

I 2 (%)

OR (95% CI)

p h

I 2 (%)

OR (95% CI)

p h

I 2 (%)

  

TT vs. CC

  

TC vs. CC

  

TT + TC vs. CC

  

TT vs. TC + CC

  

C3435T

52(15789/20274)

1.286(1.123-1.474)

0.000

71.30%

1.126(1.020-1.244)

0.000

58.20%

1.176(1.068-1.295)

0.000

61.60%

1.191(1.065-1.333)

0.000

73.00%

Cancer types

 Acute lymphoblastic leukemia (ALL)

8(1381/1459)

1.890(1.177-3.037)

0.000

77.60%

0.981(0.683-1.410)

0.001

70.10%

1.240(1.046-1.470)

0.153

34.50%

1.829(1.095-3.054)

0.000

87.30%

 Colorectal cancer

14(6362/7274)

1.047(0.875-1.254)

0.006

55.90%

1.053(0.906-1.224)

0.013

51.80%

1.054(0.907-1.225)

0.005

56.60%

1.014(0.939-1.094)

0.037

44.50%

breast cancer

9(5073/7498)

1.187(0.869-1.621)

0.001

69.30%

0.992(0.912-1.079)

0.190

28.70%

1.098(0.906-1.331)

0.024

54.80%

1.134(0.905-1.420)

0.017

57.10%

Ethnicity

Caucasian

33(12146/15989)

1.276(1.112-1.464)

0.000

60.40%

1.172(1.047-1.313)

0.000

54.9%

1.212 (1.083-1.357)

0.000

60.2%

1.062 (1.005-1.122)

0.001

47.7%

Asian

17(2966/3418)

1.314(0.894-1.933)

0.000

80.4%

1.072(0.837-1.374)

0.000

67.4%

1.153(0.915-1.453)

0.000

67.9%

1.236(0.867-1.763)

0.000

84.4%

Source of control

HB

25(5553/6173)

1.307(1.046-1.632)

0.000

69.10%

1.090(0.913-1.302)

0.000

64.60%

1.170(1.009-1.357)

0.001

54.90%

1.221(0.995-1.498)

0.000

76.80%

PB

26(10143/13992)

1.294(1.079-1.552)

0.000

73.90%

1.150(1.019-1.299)

0.001

53.20%

1.479(1.267-1.726)

0.000

77.60%

1.183(1.033-1.355)

0.000

69.60%

TT vs. CC

  

TC vs. CC

  

TT + TC vs. CC

  

TT vs. TC + CC

  

C1236T

10(2101/2842)

1.325(0.824-2.133)

0.000

77.10%

1.133(0.817-1.573)

0.005

62.20%

1.173(0.825-1.668)

0.000

70.60%

1.191(0.840-1.690)

0.000

77.80%

TT + AA + TA vs. GG

  

TG + TA vs. GG

  

TT + AA + TA + TG + TA vs. GG

  

TT + AA + TA vs. TG + TA + GG

  

G2677T/A

18(3585/4351)

1.348(1.031-1.762)

0.000

68.70%

1.096(0.986-1.218)

0.136

27.50%

1.161(1.051-1.281)

0.019

45.50%

1.278(1.022-1.597)

0.000

68.00%

Ethnicity

Caucasian

11(1728/1950)

1.363(0.921-2.016)

0.000

73.60%

1.081(0.852-1.373)

0.029

50.10%

1.149(0.899-1.467)

0.007

58.80%

1.271(0.906-1.782)

0.000

74.60%

Asian

6(1583/2040)

1.642(1.340-2.012)

0.142

39.50%

1.153(0.989-1.344)

0.804

0.00%

1.273(1.101-1.471)

0.643

0.00%

1.481(1.244-1.763)

0.192

32.50%

Source of control

HB

10(1489/2220)

1.036(0.847-1.267)

0.045

47.80%

1.025(0.874-1.202)

0.072

43.00%

1.032(0.888-1.198)

0.077

42.10%

1.028(0.867-1.219)

0.137

33.90%

PB

7(2005/2022)

1.641(1.018-2.646)

0.000

77.20%

1.164(1.008-1.345)

0.418

0.70%

1.284(1.122-1.470)

0.099

43.80%

1.537(0.998-2.366)

0.000

80.10%

  1. HB: hospital-based; PB: population-based.
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us